Jubilant Biosys France SAS

In March 2025, Jubilant Biosys Ltd, “Your CRDMO partner in science”, strengthened its European footprint through the strategic acquisition of an R&D Center of Excellence for Biologics in Saint-Julien-en-Genevois, France. This site has a rich legacy of advancing next-generation therapeutic biomolecules, with a strong focus on Biologics, including monoclonal antibodies (mAbs) and Antibody-Drug Conjugates (ADCs), and has successfully delivered multiple clinical candidates over the years. By integrating the deep scientific expertise of Jubilant Biosys France with the capabilities of our 1,200 scientists in India, we now offer a fully integrated portfolio spanning early-stage chemistry and biology research, DMPK, and end-to-end drug discovery. Our services extend through CDMO and API development, enabling seamless progression from concept to clinic. Our goal is to accelerate innovation and deliver cutting-edge solutions that address the complex challenges of modern drug development—ultimately improving patient outcomes worldwide.